Combination of Irak4 (Ca-4948) and BTK (Vecabrutinib) Inhibitors Show Superior Efficacy in Preclinical Models of Abc DLBCL Tumors Containing Myd88 -L265p Mutations

Hematological Oncology - United Kingdom
doi 10.1002/hon.195_2631
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Kym-001, a First-In-Class Oral Irak4 Protein Degrader, Induces Tumor Regression in Xenograft Models of Myd88-Mutant Abc DLBCL Alone and in Combination With BTK Inhibition

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Schnitzler Syndrome Associated With MYD88 L265P Mutation

JAAD Case Reports
Dermatology
2019English

L265P Mutation of the MYD88 Gene Is Frequent in Waldenström’s Macroglobulinemia and Its Absence in Myeloma

PLoS ONE
Multidisciplinary
2013English

Tumors With AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy With AKT Inhibitors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Pancreatic Cancer: Circulating Tumor Cells and Primary Tumors Show Heterogeneous KRAS Mutations

Scientific Reports
Multidisciplinary
2017English

Cell Line‐based Assessment of BTK Inhibitors

British Journal of Pharmacology
Pharmacology
2020English

Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the MYD88 L265P Gene Mutation

Mediterranean Journal of Hematology and Infectious Diseases
Infectious DiseasesHematology
2019English

Preclinical Efficacy of Belinostat in Combination With Zidovudine in Adult T-Cell Leukemia-Lymphoma

Retrovirology
VirologyInfectious Diseases
2015English

MEF2B Mutations Are Functionally Significant in DLBCL

Cancer Discovery
Oncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy